OSAKA, Japan--(BUSINESS WIRE)--In 2013, Glico conducted in vivo human clinical trials with Cluster Dextrin® (Highly Branched Cyclic Dextrin / HBCD). The attendant theses were reviewed, and consequently accepted for publication in the journal Bioscience, Biotechnology and Biochemistry , and are now available to readers.
The studies showed that during a cycling exercise, 24 practiced adult males experienced significantly less exhaustion after being administered 15 grams of Cluster Dextrin® than a similar group given the same amount of maltodextrin. When interviewed they described more energetic performance at both 30 and 60 minute intervals after taking Cluster Dextrin®. Additionally, blood was drawn after 30 minutes and examined for blood sugar levels, which tended to be higher in the Cluster Dextrin® group. This suggests that it offers a pronounced benefit in promoting endurance and reducing fatigue during exercise.
Cluster Dextrin® was developed by Ezaki Glico Co., Ltd. and is distributed by Glico Nutrition Co., Ltd. It offers the optimal benefit a carbohydrate-based supplement can provide in the performance of vigorous exercise.
As an energy source in sports drinks, Cluster Dextrin® has low osmotic pressure, and empties swiftly from stomach to small intestine. There it quickly breaks down to enter the bloodstream, thereby sustaining a high blood sugar level. This metabolic regime shows Cluster Dextrin® to be the most suitable supplement yet developed for drinks used in the performance of high-endurance sports.
Representatives of Glico will be on hand at Supply Side West this October (Booth 18101) to answer questions about this study.
Glico Nutrition Co., Ltd.
6-5, Utajima 4-chome, Nishi Yodogawa-ku
Osaka, 555-8502, Japan